About Us: Board of Directors
EMPOWERING A BOLD VISION
Our board members empower our culture, diversity and advancement as global leaders in a regenerative medicine company. Collectively, our advisors provide innovative solutions and industry-leading guidance to focus on patient care and medical successes made possible from their direction and insistence that only results change the way exceptional care is administered.
Mr. Panaccio was appointed as AVITA Medical Chairman of the Board in July 2014 with more than 30 years of executive leadership skills in healthcare and life sciences experience, including developing company concepts through finished commercialization.
Mr. Panaccio is positioned on additional Boards including Non-Executive Director of ASX50 company, one of the world’s largest medical diagnostics companies; Sonic Healthcare Limited since 2005; Non-Executive Director Unison Housing Limited; Non-Executive Chairman of Genera Biosystems Limited; and Non-Executive Director Rhythm Biosciences Limited. Mr. Panaccio’s past executive and board roles includ Melbourne Pathology Group, Monash IVF Group, Health Networks Australia Group and Primelife Corporation Limited.
Jeremy Curnock Cook
Jeremy is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Jeremy brings his decades of international experience to our investment team, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles.
Over his career, Jeremy has successfully managed in excess of US$1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan and Australia. Jeremy currently serves on the following boards: AVITA Medical Ltd appointed October 2012, Sea Dragon appointed October 2012, Rex Bionics Pty Ltd appointed February 2012, Armata Pharmaceuticals July 1995, SummatiX Pty Ltd appointed July 2017, Adherium Ltd appointed April 2015, JLCC Ltd appointed December 2019, Bioscience Managers UK Ltd appointed August 2017, Bioscience Managers Pty Ltd appointed January 2003, International BioScience Managers Ltd appointed March 2000, Arecor Ltd appointed October 2018, Smart Matrix Ltd appointed February 2013, and Gen InCode appointed July 2020.
Dr. Michael Perry
Dr. Michael Perry has served as a Non-Executive Director since September 28, 2022. Prior to this appointment, Dr Perry served as Non-Executive Director commencing in February 2013 until he was appointed Executive Director and Chief Executive Officer from June 2017 to September 2022. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr. Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing venture capital funds, based in San Francisco California. Dr. Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines employing RNA interference technology.
Professor Suzanne Crowe
Professor Suzanne Crowe AO, has served as a Non-Executive Director of AVITA Medical since January 2016. Australian-based, she is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, she is currently a Non-Executive Director of St Vincent’s Health Australia Ltd, the country’s largest not-for-profit health and aged care provider, and Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. She was appointed Emeritus Professor, Monash University, Melbourne in 2020. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and the university-affiliated Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research and education.
Jan Stern Reed
Ms. Reed has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Most recently, she was Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions. Prior to Solo Cup Company, she was Associate General Counsel, Corporate Secretary and Chief Corporate Governance Officer at Baxter International, Inc.. Ms. Reed currently serves as a board member of Stepan Co. (NYSE:SCL) and AngioDynamics, Inc. (NASDAQ: ANGO). Ms. Reed holds a Bachelor of Arts degree with honors in Psychology from the University of Michigan and a Juris Doctor from the Northwestern University Pritzker School of Law.
James Corbett was named Executive Director and Chief Executive Officer of the Company on September 28, 2022. Prior to this appointment, Mr. Corbett served as a Non-Executive Director from July 2021 to September 28, 2022. He has nearly 40 years of leadership experience in the Life Sciences field having served most recently as CEO of CathWorks, LTD. Mr. Corbett has extensive global commercial and operating experience, serving as an expatriate General Manager of Baxter Japan and later as General Manager and President of Scimed Life Systems Inc. and Boston Scientific International, respectively. During his career he has served as CEO of three publicly listed companies: Microtherapeutics Inc (MTIX), ev3 Inc (evvv) and Alphatec Spine (ATEC). Mr. Corbett has also led two privately funded companies as CEO: Home Diagnostics Inc. and Vertos Medical. Mr. Corbett has extensive capital markets and governance experience from both public and private environments. Mr. Corbett holds a Bachelor of Science in Business Administration from the University of Kansas.